Aclaris Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.1M
Doctors Paid
1,836
Transactions
4,914
2019 Total
$10.8M
Payment Breakdown by Category
Research$10.3M (93.3%)
Royalty/License$269,481 (2.4%)
Consulting$197,176 (1.8%)
Food & Beverage$79,948 (0.7%)
Travel$34,982 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.3M | 1,343 | 93.3% |
| Royalty or License | $269,481 | 5 | 2.4% |
| Consulting Fee | $197,176 | 65 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $161,250 | 120 | 1.5% |
| Food and Beverage | $79,948 | 3,266 | 0.7% |
| Travel and Lodging | $34,982 | 115 | 0.3% |
Payments by Type
Research
$10.3M
1,343 transactions
General
$742,837
3,571 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS | $8.3M | 0 | 761 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS | $713,463 | 0 | 182 |
| RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA | $632,429 | 0 | 192 |
| A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION | $242,426 | 0 | 88 |
| AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO | $205,073 | 1 | 47 |
| AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION | $101,155 | 0 | 35 |
| A PHASE 2A SAFETY STUDY OF ATI-502 TOPICAL SOLUTION IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | $96,701 | 1 | 27 |
| ATI-450 PRECLINICAL | $33,536 | 0 | 1 |
| A PHASE 2 OPEN LABEL STUDY OF A-101 TOPICAL SOLUTION IN SUBJECTS WITH DERMATOSIS PAPULOSA NIGRA | $26,085 | 0 | 5 |
| SK-FAN AN OPEN-LABEL STUDY ASSESSING SUBJECT SATISFACTION WITH A-101 HYDROGEN PEROXIDE TOPICAL SOLUTION, 40 WW TREATMENT FOR SEBORRHEIC KERATOSES OF THE FACE, NECK, AND DECOLLETAGE | $12,780 | 0 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED ONCE A WEEK IN SUBJECTS WITH COMMON WARTS | $10,000 | 0 | 1 |
| AN OPEN-LABEL STUDY ASSESSING SUBJECT SATISFACTION WITH A-101 HYDROGEN PEROXIDE TOPICAL SOLUTION, 40 WW TREATMENT FOR SEBORRHEIC KERATOSES OF THE FACE, NECK, AND DECOLLETAGE | $1,750 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Andrew Ondo, M.d, M.D | Dermatology | Las Cruces, NM | $214,833 | $0 |
| Dr. Raphael Clynes, M.d, M.D | General Acute Care Hospital | New York, NY | $47,742 | $0 |
| Julie Harper, Md, MD | Dermatology | Birmingham, AL | $26,338 | $0 |
| Dr. Suneel Chilukuri, Md, MD | MOHS-Micrographic Surgery | Bellaire, TX | $20,012 | $0 |
| Cherie Ditre, Md, MD | Dermatology | Radnor, PA | $18,871 | $0 |
| Dr. James Del Rosso, Do, DO | MOHS-Micrographic Surgery | Las Vegas, NV | $18,598 | $0 |
| Dr. Brian Berman, M.d., Ph.d, M.D., PH.D | Dermatology | Aventura, FL | $13,738 | $0 |
| Ms. Fran Cook-Bolden, Md, MD | Dermatology | New York, NY | $10,688 | $0 |
| Mrs. Marina Peredo, Md, MD | Dermatology | New York, NY | $10,630 | $0 |
| Dr. Pearl Grimes, Md, MD | Dermatology | Los Angeles, CA | $10,248 | $0 |
| Shawna Flanagan, Md, MD | MOHS-Micrographic Surgery | Jupiter, FL | $10,152 | $0 |
| Amy Mcmichael, Md, MD | Dermatology | Winston Salem, NC | $10,130 | $0 |
| Dr. Joshua Zeichner, Md, MD | Dermatology | New York, NY | $9,937 | $0 |
| Dr. Edward Lain, M.d, M.D | Dermatology | Austin, TX | $9,154 | $0 |
| Dr. Michelle Henry, M.d, M.D | Internal Medicine | New York, NY | $9,000 | $0 |
| Daniel Carrasco, Md, MD | Dermatology | Austin, TX | $8,897 | $0 |
| Dr. Emil Tanghetti, M.d, M.D | Dermatology | Sacramento, CA | $8,659 | $0 |
| Kimberly Grande, M.d, M.D | Specialist | Knoxville, TN | $8,573 | $0 |
| Rebecca Smith, Md, MD | Dermatology | Fort Mill, SC | $8,151 | $0 |
| Dr. Gregory Bourgeois, M.d, M.D | Dermatology | Alabaster, AL | $7,578 | $0 |
| Dr. Christopher Remishofsky, Md, MD | Dermatology | Sterling Heights, MI | $6,868 | $0 |
| Wilma Bergfeld, M.d, M.D | Dermatology | Cleveland, OH | $6,787 | $0 |
| Dr. Angela Moore, Md, Pa, MD, PA | Dermatology | Arlington, TX | $6,734 | $0 |
| Dr. Marc Inglese, M.d, M.D | Dermatology | Tallahassee, FL | $6,666 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $6,422 | $0 |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. has made $11.1M in payments to 1,836 healthcare providers, recorded across 4,914 transactions in the CMS Open Payments database. In 2019, the company paid $10.8M. The top product by payment volume is RHOFADE ($447,701).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Dermatology ($543,027 to 1,218 doctors).
Payment categories include: Food & Beverage ($79,948), Consulting ($197,176), Research ($10.3M), Travel & Lodging ($34,982), Royalties ($269,481).
Aclaris Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.